Top Markets
#1 Official Trump Official Trump +39.89%
#2 Melania Meme Melania Meme +20.05%
#3 EXOD EXOD +18.93%
#4 Movement Movement +18.56%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +17.46%
#6 Wrapped POL Wrapped POL +16.68%
#7 POL (ex-MATIC) POL (ex-MATIC) +16.52%
#8 Mubarak Mubarak +15.50%
#9 Unit Pump Unit Pump +10.98%
#10 Pump.fun Pump.fun +10.98%
Coin of the day
Official Trump Official Trump
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Classifica tra le azioni #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Prezzo delle azioni
$19.30
Ultima sincronizzazione: 2023-12-26
Capitalizzazione di mercato
$72.77M
Variazione (1 giorno)
6.22%
Variazione (1 anno)
0.00%
Paese
US
Scambia Aeglea BioTherapeutics, Inc. (AGLE)

Categoria

Healthcare
Utile per Aeglea BioTherapeutics, Inc. (AGLE)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Aeglea BioTherapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Aeglea BioTherapeutics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH